Eagle Asset Management Inc Alnylam Pharmaceuticals, Inc. Transaction History

Eagle Asset Management Inc

$16.7 Billion
Q3 2024

A detailed history of Eagle Asset Management Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Eagle Asset Management Inc holds 309,589 shares of ALNY stock, worth $76 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares

309,589

Previous 246,204 25.74%

Holding current value

$76 Million

Previous $59.8 Million 42.35%

% of portfolio

0.51%

Previous 0.33%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$233.81 - $287.01 $14.8 Million - $18.2 Million	63,385 Added 25.74%	309,589 $85.2 Million
Q2 2024 Aug 12, 2024	SELL	$143.31 - $247.0 $1.73 Million - $2.97 Million	-12,044 Reduced 4.66%	246,204 $59.8 Million
Q1 2024 May 09, 2024	SELL	$146.51 - $198.2 $676,436 - $915,089	-4,617 Reduced 1.76%	258,248 $38.6 Million
Q4 2023 Feb 12, 2024	BUY	$151.41 - $196.57 $28,010 - $36,365	185 Added 0.07%	262,865 $50.3 Million
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $636,118 - $788,396	3,725 Added 1.44%	262,680 $46.5 Million
Q2 2023 Aug 09, 2023	SELL	$185.01 - $212.05 $831,249 - $952,740	-4,493 Reduced 1.71%	258,955 $49.2 Million
Q1 2023 May 08, 2023	SELL	$182.66 - $235.53 $41,098 - $52,994	-225 Reduced 0.09%	263,448 $52.8 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $28,386 - $36,920	153 Added 0.06%	263,673 $62.7 Million
Q3 2022 Nov 07, 2022	BUY	$138.54 - $232.0 $307,143 - $514,344	2,217 Added 0.85%	263,520 $52.7 Million
Q2 2022 Aug 10, 2022	BUY	$120.42 - $169.29 $646,173 - $908,410	5,366 Added 2.1%	261,303 $38.1 Million
Q1 2022 May 12, 2022	BUY	$127.18 - $173.91 $77,198 - $105,563	607 Added 0.24%	255,937 $41.8 Million
Q4 2021 Feb 11, 2022	BUY	$159.56 - $209.29 $247,158 - $324,190	1,549 Added 0.61%	255,330 $43.7 Million
Q3 2021 Nov 10, 2021	SELL	$169.75 - $207.73 $361,228 - $442,049	-2,128 Reduced 0.83%	253,781 $47.9 Million
Q2 2021 Aug 11, 2021	SELL	$128.63 - $176.89 $32,028 - $44,045	-249 Reduced 0.1%	255,909 $43.4 Million
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $1.79 Million - $2.47 Million	14,078 Added 5.82%	256,158 $36.3 Million
Q4 2020 Feb 12, 2021	SELL	$122.97 - $147.0 $2.43 Million - $2.91 Million	-19,794 Reduced 7.56%	242,080 $31.5 Million
Q3 2020 Nov 12, 2020	BUY	$121.19 - $165.49 $6,544 - $8,936	54 Added 0.02%	261,874 $38 Million
Q2 2020 Aug 12, 2020	BUY	$104.21 - $156.44 $27.3 Million - $41 Million	261,820 New	261,820 $38.7 Million

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.

Account

Eagle Asset Management Inc Alnylam Pharmaceuticals, Inc. Transaction History